Companies: 10,795·Total market cap: $144.5T
Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTXNASDAQHealthcare● Active
$7.58
+$0.11(+1.47%)
Market Cap$331941154
P/E Ratio
52W High$13.67
52W Low$2.52
SEC Filings

Kyverna Therapeutics, Inc. (KYTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001994702 · KYTX · NASDAQ · as of Jun 8, 2026

Filing snapshot

179
Total Filings
8-K
Latest Form
2026-06-02
Most Recent
2024
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001994702 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-26
Fiscal Year End
Mar 26, 2026
Accession No.
0001193125-26-126242
Primary Document
kytx-20251231.htm
Source: data.sec.gov · CIK 0001994702 · Accession 0001193125-26-126242

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
8-KCurrent Report
8-K
2026-06-02Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-02
View
3Initial Statement of Beneficial Ownership
3
2026-05-20
View
8-KCurrent Report
8-K
2026-05-18
View
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-12
View
3Initial Statement of Beneficial Ownership
3
2026-05-06
View
8-KCurrent Report
8-K
2026-05-04
View
8-KCurrent Report
8-K
2026-04-22
View
8-KCurrent Report
8-K
2026-04-22
View
8-KCurrent Report
8-K
2026-04-20
View
ARSARS
ARS
2026-04-13
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-13
View
DEF 14AProxy Statement
DEF 14A
2026-04-13
View
EFFECTEFFECT
EFFECT
2026-04-02
View
424B5424B5
424B5
2026-04-02
View
Showing 1–15 of 133 filingsForm 4 / 144 hidden· 179 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001994702  |  Exchange: NASDAQ · Healthcare

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) has submitted 179 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2024. As a Healthcare sector company with CIK 0001994702, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Kyverna Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Kyverna Therapeutics, Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical KYTX 10-K annual reports are available from 2023 through 2026.

Investors researching Kyverna Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

KYTX SEC Filings · 8 questions

Kyverna Therapeutics, Inc. (KYTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 179 filings and access original documents at no cost. Kyverna Therapeutics, Inc.'s CIK is 0001994702.

KYTX SEC filingsKyverna Therapeutics, Inc. SEC documentsfind KYTX 10-K